[
  {
    "ts": null,
    "headline": "What Pfizer (PFE)'s Phase 3 Oncology Advances Mean for Shareholders",
    "summary": "Astellas Pharma and Pfizer recently announced positive Phase 3 results for PADCEV plus KEYTRUDA in muscle-invasive bladder cancer, while Pfizer reported encouraging findings for TUKYSA in the first-line treatment of HER2-positive metastatic breast cancer. These late-stage clinical successes highlight Pfizer's strengthened oncology pipeline and its potential to address significant treatment gaps, particularly for patients ineligible for standard therapies. We'll now explore how the promising...",
    "url": "https://finnhub.io/api/news?id=489954659f30c3e4a4c82cadffc32632b5d6caa05dd20e3749b3327eebc5a5d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760803971,
      "headline": "What Pfizer (PFE)'s Phase 3 Oncology Advances Mean for Shareholders",
      "id": 137162457,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Astellas Pharma and Pfizer recently announced positive Phase 3 results for PADCEV plus KEYTRUDA in muscle-invasive bladder cancer, while Pfizer reported encouraging findings for TUKYSA in the first-line treatment of HER2-positive metastatic breast cancer. These late-stage clinical successes highlight Pfizer's strengthened oncology pipeline and its potential to address significant treatment gaps, particularly for patients ineligible for standard therapies. We'll now explore how the promising...",
      "url": "https://finnhub.io/api/news?id=489954659f30c3e4a4c82cadffc32632b5d6caa05dd20e3749b3327eebc5a5d2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients",
    "summary": "Pharma titans Merck, Pfizer and Astellas Pharma are delivering an \"enormous new hope\" for patients with an aggressive form of bladder cancer.",
    "url": "https://finnhub.io/api/news?id=0a43e85f38c582873a9fac40836dfb192f0309f646799345caec66c069f0926b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760797840,
      "headline": "Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients",
      "id": 137162458,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pharma titans Merck, Pfizer and Astellas Pharma are delivering an \"enormous new hope\" for patients with an aggressive form of bladder cancer.",
      "url": "https://finnhub.io/api/news?id=0a43e85f38c582873a9fac40836dfb192f0309f646799345caec66c069f0926b"
    }
  },
  {
    "ts": null,
    "headline": "PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer",
    "summary": "Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as KEYNOTE-905) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor. The study evaluated the combination in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or declined cisplatin-based",
    "url": "https://finnhub.io/api/news?id=7914193eaac74770ba241b3d7a6ab5b2c4421833d6a886222fb32c40a4b8caa3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760797800,
      "headline": "PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer",
      "id": 137162460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as KEYNOTE-905) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor. The study evaluated the combination in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or declined cisplatin-based",
      "url": "https://finnhub.io/api/news?id=7914193eaac74770ba241b3d7a6ab5b2c4421833d6a886222fb32c40a4b8caa3"
    }
  },
  {
    "ts": null,
    "headline": "Did Pfizer Overpay For Yet Another Acquisition?",
    "summary": "Pfizer enters the obesity drug market with a reasonably valued deal, while valuation remains attractive and technicals show stability. See why PFE stock is a hold.",
    "url": "https://finnhub.io/api/news?id=7087527d5498ab0d0bb46fb5e2143b4af4ff288c010aa3dd60750f793e5df6f7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760779236,
      "headline": "Did Pfizer Overpay For Yet Another Acquisition?",
      "id": 137134082,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/865265104/image_865265104.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer enters the obesity drug market with a reasonably valued deal, while valuation remains attractive and technicals show stability. See why PFE stock is a hold.",
      "url": "https://finnhub.io/api/news?id=7087527d5498ab0d0bb46fb5e2143b4af4ff288c010aa3dd60750f793e5df6f7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential",
    "summary": "Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth potential. See why PFE stock is a buy.",
    "url": "https://finnhub.io/api/news?id=88a116185e882b6b581c70a1a36a1b6f695f9387d893ef43a920c1429a95420e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760776560,
      "headline": "Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential",
      "id": 137133919,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458618835/image_458618835.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth potential. See why PFE stock is a buy.",
      "url": "https://finnhub.io/api/news?id=88a116185e882b6b581c70a1a36a1b6f695f9387d893ef43a920c1429a95420e"
    }
  }
]